---
title: "Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ) — Company Overview"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002424.SZ/overview.md"
symbol: "002424.SZ"
name: "Guizhou Bailing Group Pharmaceutical Co., Ltd."
parent: "https://longbridge.com/en/quote/002424.SZ.md"
datetime: "2026-04-15T18:18:14.359Z"
locales:
  - [en](https://longbridge.com/en/quote/002424.SZ/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002424.SZ/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002424.SZ/overview.md)
---

# Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ) — Company Overview

## Basic Information

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Address | No. 212, West Route, Economic and Technological Development Zone, Anshun City, Guizhou Province |
| Website | [www.gzbl.com](https://www.gzbl.com) |

## Company Profile

Guizhou Bailing Group Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells medicines in China. It operates through four segments: Industrial, Commerce, Medical institutions, and Others The company offers medicines in various forms, including tablets, capsules, granules, syrups, powders, pills, dews, pastes, sprays, and oral liquids, as well as wines and honey. Its products are used for cardiovascular, cough, cold, gynecological, and pediatric areas. The company was incorporated in 1999 and is headquartered in Anshun, China.

## Key Executives

| Name | Title |
|------|-------|
| 牛民 | 总经理 |
| 袁远镇 | 常务副总经理 |
| 封基贤 | 副总经理 |
| 郑茂学 | 副总经理 |
| 陈培 | 副总经理 |
| 李红星 | 财务总监 |
| 陈智 | 证券事务代表 |
| 曾迤娟 | 内部审计部门负责人 |

## Major Shareholders

| Name | Ratio | Report Date |
|------|-------|-------------|
| 姜伟 | 17.55% | 2025-10-25 |
| 华创证券-证券行业支持民企发展系列之华创证券1号FOF单一资产管理计划-华创证券有限责任公司支持民企发展14号单一资产管理计划 | 6.21% | 2025-10-25 |
| 华创证券-工商银行-华创证券有限责任公司支持民企发展1号集合资产管理计划 | 5.33% | 2025-10-25 |
| 香港中央结算有限公司 | 1.01% | 2025-10-25 |
| 张明 | 0.65% | 2025-10-25 |
| 张君鹏 | 0.42% | 2025-10-25 |
| 黄琳琳 | 0.35% | 2025-10-25 |
| 吴文光 | 0.32% | 2025-10-25 |
| 李美君 | 0.30% | 2025-10-25 |
| 宋宇 | 0.29% | 2025-10-25 |

## Business Breakdown

| Segment | Revenue | Ratio |
|---------|---------|-------|
| Industrial | 2986415200 | 65.81% |
| Commercial Business | 1450705800 | 31.97% |
| Medical Institutions | 64224800 | 1.42% |
| Others | 36308200 | 0.8% |
| Intersegment Elimination | -712269500 | % |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "Guizhou Bailing Group Pharmaceutical Co., Ltd. Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Industrial",
        "ratio": 65.81
      },
      {
        "segment": "Commercial Business",
        "ratio": 31.97
      },
      {
        "segment": "Medical Institutions",
        "ratio": 1.42
      },
      {
        "segment": "Others",
        "ratio": 0.8
      },
      {
        "segment": "Intersegment Elimination",
        "ratio": null
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## Geographic Segments

| Region | Revenue | Ratio |
|--------|---------|-------|
| China | 3825384569 | 100% |


---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**